SYGNIS reports results for the first quarter of 2013

Madrid/Heidelberg (ots) -

- Operating expenses decreased by over 50 percent
- Operating result significantly improved
- U.S. patent for flagship product QualiPhi® (after period-end)
- Outlook confirmed

SYGNIS Pharma AG (Frankfurt: LIO1, ISIN: DE000A1RFM03; Prime
Standard) today announced its financial results according to IFRS for
the first quarter of 2013, ending 31 March 2013.

In the first quarter of 2013, revenues amounted to EUR0.1 million;
operating expenses amounted to EUR1.3 million. Operating expenses
include sales, general & administrative costs of EUR0.6 million as
well as research & development costs of EUR0.7 million, focused on
DNA amplification and sequencing. The resulting net loss for the
period was EUR-1.2 million.

Due to the merger of SYGNIS with X-Pol Biotech (X-Pol) effective
December 4, 2012, the results for the first quarter 2013 are not
fully comparable to the financial results reported for the prior-year
period. Following the reverse acquisition the first quarter of 2013
includes income and expenses of the old SYGNIS group and of X-Pol,
while the first quarter of the previous year only records income and
expenses of X-Pol.

Adjusted for this effect, i.e. assuming that the income and
expenses of both parts of the business would have been fully taken
into account already in the first quarter 2012, the pro forma
comparison of periods shows a significant decrease in operating
expenses by more than 50% to EUR1.3 million (pro forma Q1 2012:
EUR2.7 million) and an improvement in the operating result of 70% to
-EUR1.2 million (pro forma Q1 2012: EUR-4.0 million).

As of March 31, 2013, cash and cash equivalents amounted to EUR0.2
million (31 December 2012: EUR0.5 million). Funding of ongoing
activities is currently secured until mid-year with loan commitments
by the main shareholders. The Company has received in the first
quarter of 2013 the first tranche (EUR0.1 million) of the loan given
by the main shareholders Genetrix Life Sciences, A.B. and dievini
Hopp BioTech holding GmbH & Co. KG.

Pilar de la Huerta, CEO and CFO of SYGNIS commented: "The first
quarter was very successful for SYGNIS. Due to the implemented
restructuring measures we were able to significantly reduce our cost
base. At the same time we have reached important milestones in
product development and in April we secured a key patent for our
flagship product QualiPhi®."

Outlook

SYGNIS confirmed the outlook stated in the Annual Report 2012,
published on 30 April 2013. According to this guidance, the company
expects further commercial agreements and first revenues from product
sales in 2013. The company plans to reach break-even in 2014 fiscal
year.

Figures for the first quarter of fiscal year 2013 and comparative
figures in accordance with IFRS and pro forma figures (Q1 2012 pro
forma information includes SYGNIS old and X-Pol)

[Numbers in EUR million] Q1 2013 Q1 2012 Q1 2012
pro forma
Revenues 0.1 0.1 0.0
Total Expenses 1.3 2.7 0.3
EBIT -1.2 -4.0 -0.3
Net results for the period -1.2 4.0 -0.3
Operating Cash Flow -0.9 -1.7 -0.1
Liquidity at year-end 0.2 1.5 0.1

The interim report for the first quarter, ended 31 March 2013, is
available at www.sygnis.de.

For further information please contact:
SYGNIS Pharma AG
Pilar de la Huerta
CEO/CFO
Tel: +34-918063089
Email: pdelahuerta@sygnis.es

About SYGNIS Pharma AG: www.sygnis.de

After the merger in 2012 between X-Pol Biotech, specialising in
DNA amplification and sequencing, and SYGNIS Pharma AG, listed in the
German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN:
DE000A1RFM03), SYGNIS' new mission is to develop and distribute
technologies and products from X-Pol, which has a commercial product
in the DNA amplification segment, QualiPhi® and is currently
developing other products in the field of Next Generation Sequencing.

### Disclaimer

Some statements included in this press release, relating neither
to proven financial results nor other historical data, should be
viewed as forward-looking, i.e. not definite. Such statements are
mainly predictions of future results, trends, plans or goals. These
statements should not be considered to be total guarantees since
given their very nature they are subject to known and unknown risks
and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS
Pharma AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. SYGNIS does not
undertake to publicly update or revise these statements in the light
of new information or future results or for any other reason.

###

Contact:
SYGNIS Pharma AG
Pilar de la Huerta
CEO/CFO
Tel: +34-918063089
Email: pdelahuerta@sygnis.es